Court to Reconsider Gene Patents

July 19, 2012 at 11:40 am PT

A federal appeals court on Friday will reconsider whether isolated human genes can be patented, in a case that could reshape how biotechnology companies develop sophisticated screening tests and treatments for cancer and other diseases.

The hearing marks the latest legal twist in the fight over a series of Myriad Genetics Inc. patents relating to two genes. Mutations of the genes can signal that a woman faces greater risk of developing breast cancer or ovarian cancer. Myriad’s patents allow it to be the exclusive U.S. commercial provider of genetic screening tests for the diseases.

Read the rest of this post on the original site »

Tagged with: appeals court, biotech, biotechnology, Brent Kendall, cancer, gene patents, genes, litigation, Myriad Genetics, patents, The Wall Street Journal

Must-Reads from other Websites

Why Apple Should Buy China’s Xiaomi

Panos Mourdoukoutas, Contributor, Forbes

What I Didn’t Say

Paul Graham, Founder, ViaWeb

We Need to Talk About TED

Benjamin Bratton, Journalist, The Guardian

I, Glasshole: My Year With Google Glass

Mat Honan, Senior Writer, Wired

All Together Now

Chris Ware, Writer, The New Yorker

The Sculpture on the Moon

Corey S. Powell and Laurie Gwen Shapiro, Contributors, Slate

About Voices

Along with original content and posts from across the Dow Jones network, this section of AllThingsD includes Must-Reads From Other Websites — pieces we’ve read, discussions we’ve followed, stuff we like. Six posts from external sites are included here each weekday, but we only run the headlines. We link to the original sites for the rest. These posts are explicitly labeled, so it’s clear that the content comes from other websites, and for clarity’s sake, all outside posts run against a pink background.

We also solicit original full-length posts and accept some unsolicited submissions.